A review led by University of Miami researchers examines how delivering stem cells directly into brain-supplying arteries could support recovery after ischemic stroke and identifies the evidence still needed before the approach becomes part of standard care. Key Takeaways Researchers from the University of Miami Miller School of Medicine and collaborating institutions have published a
Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile. The results of the REMODEL trials establish remibrutinib
CHIP trial extends shelf life compared with conventional room-temperature storage Key Takeaways Extending the shelf life of platelets with refrigeration didn’t hurt their hemostatic function for people undergoing complex cardiac surgery, the landmark CHIPS trial found. Platelets stored at 1-6°C (33.8-42.8°F) for up to 21 days were noninferior to platelets stored up to 7 days
The third Clinical Trials Plenary Session at the AACR Annual Meeting 2026 was dedicated to “Cellular Therapies and Complex Immunotherapies” and provided updates on sophisticated immunotherapeutic CAR-T cells strategies, with special emphasis on their application for solid tumors. Can CAR T-cell therapy intercept disease in patients with smoldering myeloma? The first presenter Omar Nadeem, MD, of
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.
In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids. When we eat, our bodies convert extra calories, especially from carbs, sugar, fats, and alcohol, into molecules called “triglycerides”. Triglycerides are a form of fat
New options make care faster, safer, and more accessible At a glance: Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial has found three new safe and effective drug regimens for tuberculosis that is resistant to
First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling
A team of international researchers has found a drug injected under the skin effectively treats asthma and chronic obstructive pulmonary disease and reduces the need for further treatment. Dr Sanjay Ramakrishnan, from UWA’s Medical School and the Institute for Respiratory Health, was lead author of the paper published in The Lancet Respiratory Medicine. “Asthma and chronic
A device that delivers direct stimulation to the brain was found to be a safe and effective means of treating depression at home, according to a new study by researchers at UTHealth Houston; the Institute of Psychiatry, Psychology & Neuroscience at King’s College London; and the University of East London. The research was published in Nature
